Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $32.73

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have been given an average recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $32.73.

A number of research firms have recently commented on OTLK. Chardan Capital reiterated a “neutral” rating on shares of Outlook Therapeutics in a research note on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Outlook Therapeutics in a research report on Friday, November 29th. Finally, BTIG Research decreased their target price on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a research report on Friday, November 29th.

Outlook Therapeutics Stock Performance

Outlook Therapeutics stock opened at $2.30 on Monday. The business’s 50-day simple moving average is $2.87 and its 200-day simple moving average is $5.41. The firm has a market capitalization of $57.28 million, a PE ratio of -0.21 and a beta of 0.53. Outlook Therapeutics has a 52 week low of $0.87 and a 52 week high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06. Research analysts forecast that Outlook Therapeutics will post -3.84 earnings per share for the current year.

Institutional Investors Weigh In On Outlook Therapeutics

A number of institutional investors have recently added to or reduced their stakes in OTLK. Great Point Partners LLC boosted its holdings in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after purchasing an additional 221,510 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Outlook Therapeutics during the second quarter valued at approximately $232,000. AQR Capital Management LLC acquired a new stake in Outlook Therapeutics during the second quarter valued at approximately $75,000. Susquehanna Fundamental Investments LLC acquired a new stake in Outlook Therapeutics during the second quarter valued at approximately $303,000. Finally, Christensen King & Associates Investment Services Inc. acquired a new stake in Outlook Therapeutics during the third quarter valued at approximately $55,000. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.